Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Danaher Corporation    DHR

DANAHER CORPORATION

(DHR)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Danaher : Reports Third Quarter 2020 Results

10/23/2020 | 10:26am EST

WASHINGTON - Danaher Corporation (NYSE: DHR) (the 'Company') today announced results for the quarter ended October 2, 2020.

All results in this release reflect only continuing operations unless otherwise noted.

For the third quarter 2020, net earnings were $883.5 million, or $1.16 per diluted common share which represents a 38.0% year-over-year increase from the comparable 2019 period.

Non-GAAP adjusted diluted net earnings per common share were $1.72 which represents a 62.0% increase over the comparable 2019 period. Revenues increased 34.5% year-over-year to $5.9 billion, with 14.0% non-GAAP core revenue growth including Cytiva.

Operating cash flow for the third quarter 2020 was $1.7 billion, representing a 93.0% increase year-over-year, and non-GAAP free cash flow was $1.5 billion, representing a 110.0% increase year-over-year.

For the fourth quarter 2020 the Company anticipates that non-GAAP core revenue growth including Cytiva will be in the low-double digit range.

Rainer M. Blair, President and Chief Executive Officer, stated, 'We delivered outstanding third quarter results, achieving double-digit revenue growth, over 60% adjusted EPS growth, and we more than doubled our free cash flow year-over-year. Since the onset of the COVID-19 pandemic, our team has turned unprecedented challenges into impactful opportunities to support our customers and the global community, and we're proud to play a pivotal role in tackling COVID-19 head-on.'

Blair continued, 'Our performance is a testament to our associates' dedication, as they stay focused on executing for our customers during the pandemic. With the Danaher Business System as our driving force and the powerful combination of our innovative team, strong portfolio of businesses, and solid balance sheet, we believe Danaher will continue to outperform well into the future.'

ABOUT DANAHER

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 67,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.

NON-GAAP MEASURES

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, as applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.

FORWARD-LOOKING STATEMENTS

Statements in this release that are not strictly historical, including statements regarding the Company's anticipated fourth quarter and future financial performance, the Company's contributions to the response to the COVID-19 pandemic, the positioning of the Company's portfolio and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are 'forward-looking' statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the highly uncertain and unpredictable severity, magnitude and duration of the COVID-19 pandemic (and the related governmental, business and community responses thereto) on our business, results of operations and financial condition, Danaher's ability to successfully integrate the operations and employees of the Biopharma business Danaher acquired from General Electric Company (now known as Cytiva) with Danaher's existing business, the ability to realize anticipated financial, tax and operational synergies and benefits from such acquisition, Cytiva's performance and maintenance of important business relationships, the impact of our debt obligations (including the debt incurred to finance the acquisition of Cytiva) on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets (including as a result of the COVID-19 pandemic), developments and uncertainties in U.S. policy stemming from the U.S. administration, such as changes in U.S. trade and tariff policies and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors (including the impact of the United Kingdom's separation from the EU and uncertainty relating to the terms of such separation), disruptions relating to man-made and natural disasters (including pandemics such as COVID-19) and pension plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2019 Annual Report on Form 10-K and our first, second and third quarter 2020 Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

Contact:

Matthew E. Gugino

Tel: (202) 828-0850

Fax: (202) 828-0860

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about DANAHER CORPORATION
11/25DANAHER : to Present at Evercore ISI HealthCONx Conference
AQ
11/24DANAHER : To Present At Evercore ISI HealthCONx Conference
PR
11/23DANAHER : Beckman Coulter launches its semi-quantitative SARS-CoV-2 IgG II antib..
PR
11/17DANAHER : to Present at Wolfe Research Healthcare Conference
AQ
11/16DANAHER : To Present At Wolfe Research Healthcare Conference
PR
11/11DANAHER : Releases 2020 Sustainability Report
AQ
11/10DANAHER : Releases 2020 Sustainability Report
PR
11/10DANAHER : Beckman Coulter launches its SARS-CoV-2 IgM antibody test in countries..
PR
10/27DANAHER : Cytiva strengthens support to diagnostics industry with new labs, serv..
AQ
10/23DANAHER : Reports Third Quarter 2020 Results
AQ
More news
Financials (USD)
Sales 2020 21 954 M - -
Net income 2020 3 384 M - -
Net Debt 2020 15 370 M - -
P/E ratio 2020 46,4x
Yield 2020 0,33%
Capitalization 154 B 154 B -
EV / Sales 2020 7,71x
EV / Sales 2021 6,61x
Nbr of Employees 60 000
Free-Float 74,1%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | DHR | US2358511028 | MarketScreener
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 249,50 $
Last Close Price 216,78 $
Spread / Highest target 29,2%
Spread / Average Target 15,1%
Spread / Lowest Target -36,3%
EPS Revisions
Managers
NameTitle
Rainer M. Blair President, Chief Executive Officer & Director
Steven M. Rales Chairman
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Alan G. Spoon Independent Director
Walter G. Lohr Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DANAHER CORPORATION41.24%153 996
CERNER CORPORATION0.97%22 718
PERKINELMER, INC.33.12%14 474
GN STORE NORD A/S60.04%10 378
BRUKER CORPORATION-0.61%7 756
LIFETECH SCIENTIFIC CORPORATION102.01%1 827